Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis

Clinical Rheumatology

Volumn 33, Issue 3, 2014, Pages 323-328

  Kogure, Toshiaki ^a   Harada, Naoyuki ^a   Tatsumi, Takeshi ^a   Fujinaga, Hiroshi ^b  

^a Gunma Central and General Hospital   (Japan)

^b Department of Surgery   (Japan)

Author keywords

Clinical characteristics; Influenza vaccination; Predictive factor; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIBODY; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STROMELYSIN 3; TACROLIMUS; TOCILIZUMAB; TRIPLE VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION RISK; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEX; VERY ELDERLY; VIRUS STRAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED;

EID: 84896488435     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2483-0     Document Type: Article

References (25)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287-2293
2. Gluck T, Muller-Ladner U (2008) Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 46:1459-1465 (Pubitemid 351589953)
3. Naz SM, Symmons DP (2007) Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:871-883 (Pubitemid 47377805)
4. Coyne P, Hamilton J, Heycock C, Saravanan V, Coulson E, Kelly CA (2007) Acute lower respiratory tract infections in patients with rheumatoid arthritis. J Rheumatol 34:1832-1836 (Pubitemid 350067642)
5. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62:75-81
6. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403-3412 (Pubitemid 41612206)
7. Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012) Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 27:13-158
8. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D et al (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF blockers. Ann Rheum Dis 65:191-194 (Pubitemid 43131992)
9. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R et al (1994) Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 21:1203-6 (Pubitemid 24234652)
10. Kobashigawa T, Nakajima A, Taniguchi A, Inoue E, Tanaka E, Momohara S, Yamanaka H (2013) Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol [Epub ahead of print].
11. Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA et al (2006) Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65:913-918
12. De Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol 115:63-73
13. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
14. Ni Mhuircheartaigh OM, Matteson EL, Green AB, Crowson CS (2013) Trends in serious infections in rheumatoid arthritis. J Rheumatol 40:611-616
15. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285 (Pubitemid 43736578)
16. Salgado E, Gómez-Reino JJ (2011) The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol 7:329-340
17. Kim SY, Solomon DH (2010) Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 6:165-174
18. Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F, Sugiyama H, Matsushima H, Kojima T, Ohta S, Ishibe Y, Sawabe T, Ota Y, Ohishi K, Miyazato H, Nonomura Y, Saito K, Tanaka Y, Nagasawa H, Takeuchi T, Nakajima A, Ohtsubo H, Onishi M, Goto Y, Dobashi H, Miyasaka N, Harigai M (2012) Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 22:849-858
19. Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, Amelio D (2010) Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. R Clin Immunol 134:113-120
20. Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM (2007) Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 66:1402-1403 (Pubitemid 47492493)
21. Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K (2012) Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 71:2006-10
22. Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I (2011) Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 13:R209
23. Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67:937-941 (Pubitemid 351956654)
24. Aringer M (2012) Vaccination under TNF blockade-less effective, but worthwhile. Arthritis Research & Therapy 14:117
25. Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O (2011) The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 29:1643-1648